Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Role of the Endocannabinoid System in the Gynaecological Malignancy

Version 1 : Received: 31 May 2018 / Approved: 1 June 2018 / Online: 1 June 2018 (05:45:19 CEST)

How to cite: Grauso, F.; Autiero, R.; Lannino, G.R.; Zizolfi, B.; Perone, C.; Messalli, E.M. The Role of the Endocannabinoid System in the Gynaecological Malignancy. Preprints 2018, 2018060001. https://doi.org/10.20944/preprints201806.0001.v1 Grauso, F.; Autiero, R.; Lannino, G.R.; Zizolfi, B.; Perone, C.; Messalli, E.M. The Role of the Endocannabinoid System in the Gynaecological Malignancy. Preprints 2018, 2018060001. https://doi.org/10.20944/preprints201806.0001.v1

Abstract

Background: The endocannabinoid system (ECS) is a very heterogeneous array consisting of many proteins like ligands, enzymes and receptors synthetized in various tissues and immunity cells. The main endogenous ligands are unsaturated fatty acid derivatives like anandamide(AEA), 2-arachidonoylglycerol(2-AG), but many others are under study. Endocannabinoids are involved in both physiological and pathological conditions. ECS plays an important role in the regulation of main processes which lead to cancer and also in sex steroid hormone-related cancers. Methods: With focus on gynaecological cancers, main papers and review articles, up to April 2018, on the role of the ECS, were acquired by PubMed searches using the search terms: ‘cancer’, ‘cannabinoid’, ‘endocannabinoid’, ‘gynaecology’ and ‘malignancy’. Results: The review of recent literature data showed the involvement of the endocannabinoid system in numerous physiological and pathological conditions of the female genital tract up to the development of gynaecological malignancy as cervical, endometrial and ovarian cancer. Conclusions: The endocannabinoid system has an important role in antitumor actions involving different signalling receptor and receptor-independent pathways. It represents an exciting challenge to researchers for its potential use in diagnosis and treatment of all gynaecological malignancies

Keywords

endocannabinoid system; gynaecological cancers; endometrial cancer; cervical cancer; ovarian cancer, CB1R; CB2R; FAAH;

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.